Patient characteristics
The trial was terminated prematurely due to difficulty enrolling the target number of patients. Between 6 June 2016 and 27 November 2019, a total of seven patients received nintedanib 150 mg BID plus docetaxel, and seven patients received nintedanib 200 mg BID plus docetaxel (TS, The baseline characteristics of the patients were similar in both treatment groups (